vs
Chaince Digital Holdings Inc.（CD）与Prime Medicine, Inc.（PRME）财务数据对比。点击上方公司名可切换其他公司
Prime Medicine, Inc.的季度营收约是Chaince Digital Holdings Inc.的1.8倍（$838.0K vs $466.6K），Chaince Digital Holdings Inc.净利率更高（-640.5% vs -5498.7%，领先4858.2%）
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
CD vs PRME — 直观对比
营收规模更大
PRME
是对方的1.8倍
$466.6K
净利率更高
CD
高出4858.2%
-5498.7%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $466.6K | $838.0K |
| 净利润 | $-3.0M | $-46.1M |
| 毛利率 | — | — |
| 营业利润率 | -665.1% | -5800.5% |
| 净利率 | -640.5% | -5498.7% |
| 营收同比 | — | -61.6% |
| 净利润同比 | — | -9.0% |
| 每股收益（稀释后） | $-0.05 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDPRME
| Q4 25 | — | $838.0K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $466.6K | $1.1M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $2.2M | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $591.0K | ||
| Q4 23 | — | $0 |
净利润CDPRME
| Q4 25 | — | $-46.1M | ||
| Q3 25 | — | $-50.6M | ||
| Q2 25 | $-3.0M | $-52.6M | ||
| Q1 25 | — | $-51.9M | ||
| Q4 24 | — | $-42.3M | ||
| Q2 24 | — | $-55.3M | ||
| Q1 24 | — | $-45.8M | ||
| Q4 23 | — | $-65.6M |
营业利润率CDPRME
| Q4 25 | — | -5800.5% | ||
| Q3 25 | — | -4406.0% | ||
| Q2 25 | -665.1% | -4787.2% | ||
| Q1 25 | — | -3603.3% | ||
| Q4 24 | — | -2025.7% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -8179.5% | ||
| Q4 23 | — | — |
净利率CDPRME
| Q4 25 | — | -5498.7% | ||
| Q3 25 | — | -4129.1% | ||
| Q2 25 | -640.5% | -4716.7% | ||
| Q1 25 | — | -3568.8% | ||
| Q4 24 | — | -1936.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -7743.0% | ||
| Q4 23 | — | — |
每股收益（稀释后）CDPRME
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | $-0.05 | $-0.41 | ||
| Q1 25 | — | $-0.40 | ||
| Q4 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.46 | ||
| Q1 24 | — | $-0.44 | ||
| Q4 23 | — | $-0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.2M | $63.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $29.4M | $120.9M |
| 总资产 | $36.6M | $342.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDPRME
| Q4 25 | — | $63.0M | ||
| Q3 25 | — | $71.4M | ||
| Q2 25 | $27.2M | $53.8M | ||
| Q1 25 | — | $91.9M | ||
| Q4 24 | — | $182.5M | ||
| Q2 24 | — | $55.6M | ||
| Q1 24 | — | $94.2M | ||
| Q4 23 | — | $41.6M |
股东权益CDPRME
| Q4 25 | — | $120.9M | ||
| Q3 25 | — | $161.8M | ||
| Q2 25 | $29.4M | $60.9M | ||
| Q1 25 | — | $106.9M | ||
| Q4 24 | — | $153.1M | ||
| Q2 24 | — | $196.6M | ||
| Q1 24 | — | $243.8M | ||
| Q4 23 | — | $133.1M |
总资产CDPRME
| Q4 25 | — | $342.7M | ||
| Q3 25 | — | $385.0M | ||
| Q2 25 | $36.6M | $279.0M | ||
| Q1 25 | — | $328.2M | ||
| Q4 24 | — | $297.5M | ||
| Q2 24 | — | $259.7M | ||
| Q1 24 | — | $311.4M | ||
| Q4 23 | — | $193.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-37.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-37.5M |
| 自由现金流率自由现金流/营收 | — | -4480.4% |
| 资本支出强度资本支出/营收 | — | 34.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-167.1M |
8季度趋势，按日历期对齐
经营现金流CDPRME
| Q4 25 | — | $-37.3M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | $-1.3M | $-41.4M | ||
| Q1 25 | — | $-48.9M | ||
| Q4 24 | — | $16.2M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-67.7M | ||
| Q4 23 | — | $-43.9M |
自由现金流CDPRME
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | — | $-70.0M | ||
| Q4 23 | — | $-45.7M |
自由现金流率CDPRME
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11849.6% | ||
| Q4 23 | — | — |
资本支出强度CDPRME
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | — | 82.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 393.2% | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
